open access

Vol 90, No 2 (2019)
REVIEW PAPERS Gynecology
Published online: 2019-02-28
Get Citation

Food and drug administration — approved molecular methods for detecting human papillomavirus infection

Katarzyna Sitarz, Slawa Szostek
DOI: 10.5603/GP.2019.0018
·
Pubmed: 30860278
·
Ginekol Pol 2019;90(2):104-108.

open access

Vol 90, No 2 (2019)
REVIEW PAPERS Gynecology
Published online: 2019-02-28

Abstract

In the world, there are many tests that allow the detection of HPV infection. These tests are based on different operating principles and have different levels of sensitivity. The first test to detect HPV infection was approved by the Food and Drug Administration in 2003. Since then, the FDA has approved five more commercial tests for this purpose, the last one in 2018. This paper discusses the principles of molecular tests to detect HPV, which have been approved by the FDA, the main differences between them, as well as their advantages and disadvantages. 

Abstract

In the world, there are many tests that allow the detection of HPV infection. These tests are based on different operating principles and have different levels of sensitivity. The first test to detect HPV infection was approved by the Food and Drug Administration in 2003. Since then, the FDA has approved five more commercial tests for this purpose, the last one in 2018. This paper discusses the principles of molecular tests to detect HPV, which have been approved by the FDA, the main differences between them, as well as their advantages and disadvantages. 

Get Citation

Keywords

HPV detection; Hybrid Capture; Cervista; COBAS; Aptima; Onclarity

About this article
Title

Food and drug administration — approved molecular methods for detecting human papillomavirus infection

Journal

Ginekologia Polska

Issue

Vol 90, No 2 (2019)

Pages

104-108

Published online

2019-02-28

DOI

10.5603/GP.2019.0018

Pubmed

30860278

Bibliographic record

Ginekol Pol 2019;90(2):104-108.

Keywords

HPV detection
Hybrid Capture
Cervista
COBAS
Aptima
Onclarity

Authors

Katarzyna Sitarz
Slawa Szostek

References (35)
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Human Papillomavirus and Related Diseases Report. Barcelona: HPV Information Centre. http://www.hpvcentre.net/statistics/reports/POL.pdf (2018).
  3. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4): 244–265.
  4. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 2–13.
  5. Abreu ALP, Souza RP, Gimenes F, et al. A review of methods for detect human Papillomavirus infection. Virol J. 2012; 9: 262.
  6. Krajowa Izba Diagnostów Laboratoryjnych; Polskie Towarzystwo Ginekologiczne. Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL). Ginekol Pol. 2013; 84: 395–399.
  7. Olejniczak T, Rabiega-Gmyrek D, Niepsuj-Biniaś J, et al. [Human papilloma virus genotyping in women with abnormal cytology]. Ginekol Pol. 2015; 86(7): 541–546.
  8. Wong AA, Fuller J, Pabbaraju K, et al. Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol. 2012; 50(1): 25–29.
  9. Hybrid CaptureTM II. Gaithersburg: Digene Corporation. https://www.accessdata.fda.gov/cdrh_docs/pdf/P890064S009c.pdf. (2012).
  10. Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol. 2010; 48(2): 554–558.
  11. Bozzetti MC, Nonnenmacher B, Mielzinska I, et al. Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Annals of Epidemiology. 2000; 10(7): 466.
  12. Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol. 2004; 191(5): 1590–1597.
  13. Kulmala SM, Syrjänen S, Shabalova I, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol. 2004; 42(6): 2470–2475.
  14. Peyton CL, Schiffman M, Lörincz AT, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998; 36(11): 3248–3254.
  15. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol. 2008; 46(8): 2595–2604.
  16. Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003; 41(9): 4022–4030.
  17. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011; 20(7): 1398–1409.
  18. Cervista ™ HPV HR. Madison: Third Wave Technologies. https://www.accessdata.fda.gov/cdrh_docs/pdf8/p080014c.pdf (2008).
  19. Kurian EM, Caporelli ML, Baker S, et al. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am J Clin Pathol. 2011; 136(5): 808–816.
  20. Marras SAE. Selection of fluorophore and quencher pairs for fluorescent nucleic acid hybridization probes. Methods Mol Biol. 2006; 335: 3–16.
  21. Alameda F, Garrote L, Mojal S, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med. 2015; 139(2): 241–244.
  22. Torres M, Fraile L, Echevarria Jm, et al. Human Papillomavirus (HPV) Genotyping: Automation and Application in Routine Laboratory Testing. Open Virol J. 2012; 6: 144–150.
  23. Cervista ™ HPV 16/18. Madison: Third Wave Technologies. https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080015c.pdf (2008).
  24. Bartholomew DA, Luff RD, Quigley NB, et al. Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples. J Clin Virol. 2011; 51(1): 38–43.
  25. cobas® HPV Test. South Branchburg: Roche Molecular Systems. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100020s017c.pdf (2015).
  26. Rao A, Young S, Erlich H, et al. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013; 51(5): 1478–1484.
  27. Heideman DAM, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011; 49(11): 3983–3985.
  28. Preisler S, Rebolj M, Ejegod DM, et al. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study. BMC Cancer. 2016; 16: 510.
  29. APTIMA® HPV Assay. San Diego: Gen-Probe Incorporated. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100042c.pdf (2011).
  30. Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011; 49(2): 557–564.
  31. Castle PE, Eaton B, Reid J, et al. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. J Clin Microbiol. 2015; 53(4): 1277–1281.
  32. BD Onclarity™ HPV Assay. Sparks: Becton, Dickinson and Company. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160037C.pdf (2018).
  33. Ejegod DM, Junge J, Franzmann M, et al. Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples. Papillomavirus Res. 2016; 2: 31–37.
  34. Bottari F, Sideri M, Gulmini C, et al. Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions. J Clin Microbiol. 2015; 53(7): 2109–2114.
  35. Guo M, Khanna A, Feng J, et al. Analytical performance of cervista HPV 16/18 in SurePath pap specimens. Diagn Cytopathol. 2015; 43(4): 301–306.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl